Emerging agents that target signaling pathways in cancer fibroblast cells (Review)
International Journal of Oncology · 2026
DOI: 10.3892/ijo.2026.5900 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Oncology, 2026. Verfasst von Yan Wan und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Anhui College of Traditional Chinese Medicine, Wuhu, Anhui 241000, P.R. China. Hauptthemen laut MEDLINE: Signal Transduction, Cancer-Associated Fibroblasts, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 171 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Cancer‑associated fibroblasts (CAFs) play a critical role in cancer development, recurrence and metastasis. Several signaling pathways are crucial in CAF development, including fibroblast activation protein (FAP), phosphoinositide 3‑kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR), Janus kinase/signal transducers and activators of transcription (JAK/STAT), nuclear factor κB (NF‑κB), transforming growth factor β (TGF‑β), ferroptosis, apoptosis and autophagy pathways. Targeting the ferroptosis signaling pathway specifically kills CAFs. Therefore, targeting these pathways may inhibit the protumorigenic functions of CAFs. Small molecule drugs, due to their well‑dispersed spatial structures and distinct chemical properties, exhibit promising druggability and pharmacokinetic profiles. These characteristics make small molecule drugs highly advantageous in drug development and increasingly favored in the market. The present review summarized current studies on small molecule compounds that inhibit CAF progression, encompassing inhibitors of the PI3K/AKT/mTOR, JAK/STAT, TGF‑β and NF‑κB pathways, as well as activators of the FAP, ferroptosis, apoptosis and autophagy pathways. These small molecule compounds underscore the significance of CAFs in tumor progression and suggest novel strategies for cancer treatment by targeting CAFs in clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Anhui College of Traditional Chinese Medicine, Wuhu, Anhui 241000, P.R. China.
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 611137, P.R. China.
Zitieren
APA
Wan, Y., Liu, X. Q., Liu, D., Li, K. D., & Zhang, D. D. (2026). Emerging agents that target signaling pathways in cancer fibroblast cells (Review). International Journal of Oncology. https://doi.org/10.3892/ijo.2026.5900
Vancouver
Wan Y, Liu XQ, Liu D, Li KD, Zhang DD. Emerging agents that target signaling pathways in cancer fibroblast cells (Review). International Journal of Oncology. 2026. doi:10.3892/ijo.2026.5900
BibTeX
@article{Wan2026,
author = {Wan, Yan and Liu, Xiang-Qing and Liu, Dong and Li, Ke-Di and Zhang, Dan-Dan},
title = {Emerging agents that target signaling pathways in cancer fibroblast cells (Review)},
journal = {International Journal of Oncology},
year = {2026},
doi = {10.3892/ijo.2026.5900}
}
EUVIMED